NEW YORK, Aug. 17 /PRNewswire-FirstCall/ -- Pfizer Inc said today that
a federal court jury in the Eastern District of Virginia (Alexandria) has
ruled unanimously that Pfizer does not infringe Synthon IP's U.S. patent
covering a process for making amlodipine, the active ingredient in Norvasc.
Norvasc is the world's most-prescribed branded medicine for treating
hypertension.
The jury also found that the patent is invalid on multiple grounds.
"Today's unanimous decisions underscore our determination to defend our
products against unwarranted attacks and to support research-based medical
innovations that benefit millions of patients," said Allen Waxman, Pfizer's
general counsel.
Synthon IP, a U.S. subsidiary of Dutch company Synthon BV, brought its
suit against Pfizer in November 2005, asserting that Pfizer infringed a
Synthon patent issued in 2003. This patent, Synthon claimed, covered
Pfizer's process for making amlodipine -- a process Pfizer had not only
published but has been using for over 15 years.
SOURCE Pfizer Inc
 back to top
Related links:
http://www.pfizer.com
Photo Notes:A free corporate logo to accompany this
story is availableimmediately via Wieck Photo Database to any
media with telephoto receiveror electronic darkroom, PC or
Macintosh, that can accept overheadtransmissions. To retrieve a
logo, please call 972-392-0888./ /Company News On-Call:
http://www.prnewswire.com/comp/688250.html
Pfizer's press releases are available through PR Newswire's
Company News On-Call service on PRN's Web Site. Visit
http://www.prnewswire.com/comp/688250.html/
CONTACT:
Bryant Haskins for Pfizer, +1-212-733-8719
|
